Find out more about the latest RNA drug development
22.08.2023 Munich’s leading researchers have preclinically evaluated an active RNA Drug called RCS-21 to prevent severe pneumonia and fibrosis, caused by infections such as SARS-CoV2 (Beck et al. 2023). Macrophage-targeted carbohydrate-coupled antimiR-21 (RCS-21) enables an efficient transport mechanism to pathological tissues and inhibits the activity of the microRNA 21 molecule. AntimiR-21 oligos were synthesized and modified with Trimannose and GalNac depending on baseclick patented technology. Modified antimir-21 exhibited a distinct cellular targeting in tissue. We are proud to support the idea development of our partners based on our expertise.